비씨월드제약

200780KOSDAQ의약품 제조업

43.3 / 100

Reference Date: 2026-04-13

Financial Score11.0 / 40

News Sentiment16.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Declined 13.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

BC World Pharm focuses on R&D of new and improved drugs, maintaining competitiveness in both domestic and international markets by exporting specialty pharmaceuticals produced in facilities compliant with FDA and EMA standards. The company is expanding its CMO/CDMO business and pursuing overseas licensing deals, addressing growing pharmaceutical demand driven by aging populations.

Number of Employees

288people

Average Salary

40.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 14.804.0Point

PBR

0.58Industry Average 1.045.5Point

Lower than industry avg (good)

ROE

-4.23Industry Average 4.420.0Point

Well below industry avg

Debt Ratio

20.12Industry Average 11.980.5Point

1.7x industry avg (risky)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼21.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -1.6% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 0Negative 0Average Sentiment Score 80

Positive
비씨월드헬스케어, 소아 중증 침흘림 치료제 ‘시알라나액’ 국내 공...
계열사 비씨월드헬스케어가 소아 중증 침흘림 치료제 '시알라나액'을 국내에 출시하고 공급을 시작하여 신규 매출 발생이 기대됩니다.

Detailed Momentum

52-week position3.0Point

52w lower range (23%)

Current 4,310Won52-week high 5,87052-week low 3,842

1-month return1.0Point

1m -13.37% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-01